Halozyme Therapeutics, Inc.  

(Public, NASDAQ:HALO)   Watch this stock  
Find more results for HALO
-0.12 (-0.64%)
Feb 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 18.46 - 18.92
52 week 11.41 - 21.13
Open 18.71
Vol / Avg. 0.00/1.24M
Mkt cap 2.64B
P/E     -
Div/yield     -
EPS -0.68
Shares 142.36M
Beta 1.98
Inst. own 90%
May 4, 2018
Halozyme Therapeutics Inc Annual Shareholders Meeting (Estimated) - 11:00AM EDT - Add to calendar
Mar 13, 2018
Halozyme Therapeutics Inc at Cowen Health care Conference - 9:20AM EDT - Add to calendar
Feb 20, 2018
Q4 2017 Halozyme Therapeutics Inc Earnings Call - 4:30PM EST - Add to calendar
Feb 20, 2018
Q4 2017 Halozyme Therapeutics Inc Earnings Release - 4:00PM EST - Add to calendar
Jan 9, 2018
Halozyme Therapeutics Inc at JPMorgan Healthcare Conference - Webcast
Dec 14, 2017
Halozyme Therapeutics Inc at BMO Capital Markets Prescriptions for Success Healthcare Conference
Nov 29, 2017
Halozyme Therapeutics Inc at Piper Jaffray Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin 4.31% -70.23%
Operating margin 12.67% -56.72%
EBITD margin - -55.08%
Return on average assets 3.14% -46.48%
Return on average equity 16.89% -1958.98%
Employees 259 -
CDP Score - -


11388 Sorrento Valley Rd
SAN DIEGO, CA 92121-1345
United States - Map
+1-858-7948889 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex recombinant. The Company's development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).

Officers and directors

Connie L. Matsui Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Helen I Torley President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Laurie D. Stelzer Chief Financial Officer, Senior Vice President
Age: 49
Bio & Compensation  - Reuters
Harry J. Leonhardt Esq. Senior Vice President, Chief Compliance Officer, General Counsel
Age: 60
Bio & Compensation  - Reuters
Athena M. Countouriotis M.D. Senior Vice President, Chief Medical Officer
Age: 45
Bio & Compensation  - Reuters
Jean-Pierre Bizzari M.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
James M. Daly Independent Director
Age: 55
Bio & Compensation  - Reuters
Jeffrey William Henderson Independent Director
Age: 52
Bio & Compensation  - Reuters
Kenneth J. Kelley Independent Director
Age: 57
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Randal J. Kirk Independent Director
Age: 63
Bio & Compensation  - Reuters